Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra Pahlajani

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

Clinical outcomes in women with metastatic HER2-low breast cancer in the real worldПодробнее

Cancer and Us gets a port for breast cancer HER2 Positive Chemo treatmentПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?Подробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in ReviewПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

HER2-low expression in breast cancerПодробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее

New treatment for HER2 low metastatic breast cancer (HB 422)Подробнее

ASCO 2022: Metastatic Breast Cancer Drug Therapy RecapПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее

The latest news on the management of breast cancer patients with brain metastasesПодробнее

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated w...Подробнее

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancerПодробнее

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast CancerПодробнее